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ABstrAct
Taxanes (paclitaxel and docetaxel) are antimicrotubule agents used in the clinical 
practice for the treatment of solid tumors. The molecular mechanisms of taxane-	
dependent cytotoxicity are only partially known. In vitro, different modes of action have 
been established for paclitaxel according to its concentration. A similar phenomenon 
has been shown for other microtubule-stabilizing drugs, including docetaxel. Recently, 
we described two different forms of mitotic exit in breast cancer cell lines exposed to 
docetaxel. The causes and consequences of the dual mechanism of cytotoxicity of this 
agent are discussed here.
AntiMicrotuBule AGents And Known MecHAnisMs of cell deAtH
Dynamic	 instability	 describes	 the	 process	 of	 slow	 growth	 and	 rapid	 shortening	 of	
microtubules	by	continuous	addition	and	loss	of	tubulin	at	their	ends.1	The	precise	regu-
lation	of	this	process	is	fundamental	to	the	multiple	functions	of	microtubules,	especially	
those	related	with	cell	division.2	Several	agents	affecting	microtubule	dynamics	have	been	
shown	to	be	effective	against	 tumor	cells.	They	are	classified	 into	 those	 inducing	either	
microtubule	depolymerization	or	their	polymerization.	The	 last	group	is	 represented	by	
taxanes,	which	include	paclitaxel	and	docetaxel,	both	currently	approved	for	clinical	use.3,4	
By	binding	to	the	b	subunit	of	tubulin,	these	agents	impair	the	dynamic	of	microtubules,	
promote	their	polymerization,	and	arrest	the	cells	in	mitosis.	As	a	consequence,	cells	die	
by	apoptosis	through	pathways	still	not	fully	characterized.
Most	 studies,	 especially	 with	 paclitaxel,	 have	 shown	 cell	 cycle	 arrest	 in	mitosis	 as	 a	
necessary	step	for	cell	death.	However,	it	is	also	necessary	that	cells	overcome	this	arrest,	
advancing	 to	 interphase	 without	 cytokinesis	 (a	 process	 called	 mitotic	 slippage),	 and	
entering	a	 tetraploid	or	“pseudo-G1”	phase	 followed	by	apoptotic	cell	death.
5,6	Mitotic	
arrest	 induced	by	 taxanes	 is	 dependent	on	 the	 activation	of	 the	 spindle-assembly	 check-
point,	which	monitors	any	defects	in	microtubule-kinetochore	attachment	or	in	the	tension	
of	the	mitotic	spindles.	This	checkpoint	is	usually	weakened—but	not	absent—in	human	
tumor	cells,	with	cells	able	to	respond	with	an	initial	cell	cycle	arrest	but	less	able	to	main-
tain	it.7,8	Therefore,	tumor	cells	usually	arrest	in	response	to	taxanes,	but	this	arrest	is	weak	
or	transitory	permitting	the	mitotic	slippage	required	for	cells	to	die.
Several	 questions	 still	 remain	 to	 be	 answered	 regarding	 the	 mechanisms	 of	 taxane-	
dependent	 cytotoxicity	 in	 tumor	 cells,	 including	 the	 induction	 of	 cell	 death	 without	
mitotic	 arrest	 in	 some	 experimental	 conditions,	 the	 dependence	 of	 these	 processes	 on	
transcriptional	mechanisms,	 the	 importance	of	 a	 functional	p53	protein,	 and	 the	 exact	
mechanism(s)	by	which	tumor	cells	die.
Mitotic exit After exPosure to tAxAnes
Recently,	we	described	a	dual	mechanism	of	action	for	docetaxel	in	breast	cancer	cell	
lines,9	that	was	suggested	by	a	biphasic	growth	inhibition	curve.	The	presence	of	at	least	
two	mechanisms	of	action	was	confirmed	by	 the	observation	of	different	cell	 cycle	and	
cell	death	profiles	in	both	cell	 lines,	and	further	studied	by	gene	expression	microarrays	
performed	 after	 two	 concentrations	 of	 docetaxel.	 The	 most	 striking	 differences	 were	
found	at	the	 level	of	cell	cycle.	Low	concentrations	(2–4	nM)	induced	aberrant	mitosis	
followed	 by	 aneuploidy,	 whereas	 higher	 concentrations	 (100	 nM)	 induced	 sustained	
mitotic	arrest	followed	by	mitotic	slippage	(Fig.	1).	Although	mitotic	arrest	and	mitotic	
slippage	are	well	characterized	responses	to	this	agent,	there	are	also	some	previous	reports	
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indicating	that	docetaxel	is	able	to	induce	aberrant	mitosis	at	lower	
concentrations.10,11	However,	most	studies	indicating	a	dual	mecha-
nism	 of	 action	 of	 taxanes	 had	 been	 reported	 with	 paclitaxel.12-15	
In	 accordance	 to	 our	 findings	 with	 docetaxel,	 Ikui	 et	 al	 reported	
that	higher	 concentrations	of	paclitaxel	 induce	 a	 longer	 spindle-as-
sembly	 checkpoint	 in	 HeLa	 cells.	 In	 contrast,	 low	 concentrations	
of	paclitaxel	cause	mitotic	delay	followed	by	premature	dissociation	
of	 p55CDC/CDC20	 from	 Mad2	 and	 BubR1	 and	 abrogation	 of	
the	spindle-assembly	checkpoint,	leading	to	aneuploidy.16	As	repre-
sented	in	Figure	1,	mitotic	exit	will	be	produced	through	at	least	two	
possible	processes	depending	on	drug	concentration.	Concentrations	
known	to	stabilize	 the	microtubules,	 induce	a	prolonged	activation	
of	the	spindle-assembly	checkpoint	(the	mitotic	index	was	maximal	
after	24	hours).	This	is	followed	by	mitotic	slippage,	and	manifested	
by	multinucleation.	In	contrast,	 low	concentrations	of	docetaxel	will	
affect	 the	 dynamics	 of	microtubules,	 inducing	 a	 transient	 activation	
of	 the	 spindle-assembly	 checkpoint.	 In	 the	 breast	 cancer	 cells	 that	
we	 evaluated,	 this	 checkpoint	 is	 not	 strong	 enough	 to	 stop	 the	
segregation	of	chromosomes,	and	this	is	manifested	by	aneuploidy.17	
Aneuploidy	is	known	to	be	the	result	of	aberrant	mitosis	which	can	
be	 caused	 by	 divisions	 in	 the	 presence	 of	 a	multipolar	 spindle,	 as	
has	been	described	for	docetaxel.	However,	 it	can	also	be	the	result	
of	 previous	 defects	 in	 cytokinesis	 or	 centrosome	 amplification,	 by	
defects	 in	chromosome	cohesion,	by	spindle	attachment	defects,	or	
by	 impairment	 of	 the	 mitotic	 checkpoint	 response.7	 Interestingly,	
although	docetaxel	has	been	described	to	interfere	with	centrosome	
duplication	during	S	phase,	cells	synchronized	in	G2	and	treated	with	
2	nM	docetaxel	during	6	hours,	were	still	able	to	show	aneuploidy	
after	passing	 through	mitosis.	This	 suggests	 that	mechanisms	 inde-
pendent	of	centrosome	duplication	are	related	with	the	induction	of	
aberrant	mitosis	in	this	context.
Our	gene	expression	data	 supports	 some	of	 these	previous	 find-
ings.	Favoring	the	stronger	mitotic	arrest	with	higher	concentrations	
of	docetaxel,	an	induction	of	mitosis-related	genes	(AURKA, PLK1)	
was	 observed	 in	 this	 condition	 (Fig.	 2).	 Checkpoint-related	 genes	
(BUB1, MAD2L1)	showed	a	similar	profile	 in	the	first	 time	points	
of	treatment.	However,	as	can	be	seen	in	Figure	2,	a	downregulation	
of	these	transcripts	was	observed	after	48	hours.	This	can	be	related	
to	a	release	from	the	spindle	checkpoint	and	the	induction	of	mitotic	
slippage.	 Although	 exit	 from	 a	 normal	 mitosis	 is	 controlled	 by	
ubiquitin-dependent	proteolysis	and	phosphorylation/dephosphory-
lation	events,	it	is	possible	that	transcriptional	regulation	participates	
in	the	prolonged	activation	of	the	spindle-assembly	checkpoint	after	
Figure 1. Exit from mitosis after exposure to docetaxel. The effect of docetaxel 
on cell cycle is represented here after a synchronization experiment. Cells 
normally replicating their DNA from G1 (2n) to G2 (4n) are then subjected 
to low and high concentrations of the drug. Cells not receiving treatment exit 
normal mitosis (M) to start a new cell cycle from G1 (1). In contrast, low and 
high concentrations of docetaxel induce transient (3) or prolonged (2) arrest 
in mitosis, respectively. The respective cell cycle profiles (obtained by DNA 
staining with propidium iodide) are shown.
Figure 2. Transcriptional responses to docetaxel. Gene expression profiles 
of selected transcripts after treatment of MCF7 cells with 2 concentrations 
of docetaxel (4 nM and 100 nM), and different time points (8, 24 and 
48 hours). Gene expression is represented as units relative to nontreated cells.
Docetaxel	Therapy	in	Cancer	Cell	Lines
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taxane	exposure.	 In	 support	of	 this	view,	 the	 results	of	Chen	et	 al.	
suggest	that	the	mitotic	slippage	induced	by	microtubule-stabilizing	
drugs	 may	 result	 from	 altered	 transcriptional	 regulation	 of	 G2/M	
and	 spindle	 checkpoint	 genes	when	 higher	 concentrations	 of	 drug	
are	 used.15	 Finally,	 we	 observed	 a	 different	 expression	 profile	 of	
known	 p53	 targets	 when	 comparing	 low	 and	 high	 concentrations	
of	 docetaxel	 in	 the	 p53-functional	 cell	 line	 MCF7.	 Specifically,	
p21	and	TP53INP1	were	induced	at	earlier	time	points	with	lower	
concentrations.	In	addition,	there	was	an	inverse	correlation	between	
p53	protein	accumulation	and	p21	transcript	and	protein	expression	
(Figs.	 2	 and	 3).	This	 observation	 supports	 a	model	 in	 which	 p53	
protein	accumulation	 is	a	marker	of	 the	 timing	of	mitotic	arrest.18	
In	addition,	the	earlier	induction	of	p21	after	low	concentrations	of	
docetaxel	may	 be	 related	with	 the	mechanism	 of	 aberrant	mitosis,	
as	 has	 been	 reported.19	 In	 fact,	 previous	 studies	 have	 suggested	
that	p21	 is	not	required	 for	 the	mitotic	arrest	 in	response	 to	pacli-
taxel,	 but	 instead	 it	 could	 have	 a	 role	 in	 facilitating	 the	 exit	 from	
abnormal	mitosis.20
Together,	these	data	point	to	a	mechanism	regulating	the	different	
consequences	 of	 docetaxel	 exposure	 according	 to	 the	 duration	 of	
mitotic	 arrest.	 This	 mechanism	 can	 be	 partially	 regulated	 at	 the	
transcriptional	level	by	changes	both	in	p21	and	checkpoint	genes.
A duAl MecHAnisM iMPlies duAl outcoMes
Induction	of	apoptosis	has	been	described	as	a	main	mechanism	
of	 cell	 death	 after	 antimicrotubule	 agents,	 implicating	 different	
downstream	events	 including	 the	dysregulation	of	 cell	 cycle-related	
proteins	(particularly	p34cdc-2),21	the	activation	of	the	jun	N-terminal	
kinase	(JNK)22	and	Raf-1	kinase23,24	pathways, and the final induc-	 	 	 	
tion	of	a	misbalance	of	the	Bcl-2	family	of	proteins.22,24-27	However,	
two	different	effects	on	mitosis	that	we	described	were	also	followed	
by	different	types	of	cell	death	(Fig.	3).	Although	100	nM	docetaxel	
induced	 a	 clear	 pattern	 of	 early	 apoptosis	 by	 Annexin-V	 staining	
at	 short	 time	 points	 (24	 hours	 or	 less),	 cell	 death	 was	 lower	 with	
2–4	nM	concentrations,	and	it	was	mainly	represented	by	necrosis.9	
This	is	consistent	with	reports	showing	that	cells	undergoing	aberrant	
mitosis	eventually	result	in	reduced	clonogenic	survival,28,29	usually	
due	to	nonapoptotic	mechanisms.30	In	this	sense,	some	groups	have	
described	alternative	caspase-independent	mechanisms	of	cell	death	
after	 taxane	 therapy.31	More	 recently,	 it	was	 shown	that	autophagy	
can	be	an	important	form	of	programmed	cell	death	after	treatment	
of	MCF7	breast	 cancer	 cells	with	paclitaxel	 analogs	 and	docetaxel,	
by	 using	MAP	 I	 LC3	 antibody	 as	 an	 specific	marker	 of	 autopha-
gosomes.32	Therefore,	 the	most	 likely	 scenery	 is	 a	 combination	 of	
apoptotic	and	nonapoptotic	mechanisms.	In	fact,	a	known	mediator	
of	 apoptosis	 after	 taxane	 therapy	 is	 the	 cell	 death	 receptor	CD95/
FAS.	 Our	 own	 gene	 expression	 data	 shows	 that	 the	 induction	 of	
FAS is	a	common	response	to	docetaxel.	Moreover,	this	response	was	
dose-	and	cell	line-independent	(Fig.	2).	However,	it	is	possible	that	
nonapoptotic	pathways	override	the	induction	of	FAS	after	aberrant	
mitosis	 induced	 by	 low	 concentrations	 of	 docetaxel.	 One	 possible	
mechanism	triggering	cell	death	 in	 this	 context	 is	 the	 induction	of	
DNA	damage.	It	is	likely	that	aberrant	mitosis	creates	chromosomal	
breakage,	 interchromosomal	 concatenation	 and	 a	 lethal	 genetic	
imbalance	that	leads	to	cell	death.5,33	In	this	sense,	we	have	observed	
accumulation	 of	 phospho-H2AX	 after	 docetaxel,	 especially	 in	 the	
p53-non	 functional	MDA-MB-231	 cells,	 at	 low	 concentrations	 of	
docetaxel.	In	addition,	it	was	recently	shown	that	DNA	damage	can	
be	also	involved	in	the	activation	of	the	G1	checkpoint	after	mitotic	
slippage	induced	by	antimitotic	agents.34
concludinG reMArKs
The	 impairment	 of	 microtubule	 dynamics	 results	 in	 cell	 cycle	
alterations	and	cell	death.	Both	effects	can	be	the	result	of	independent	
activities	of	docetaxel.	However,	our	observations	point	to	the	possi-
bility	that	the	mechanism	of	cell	death	is	the	direct	consequence	of	
the	previous	type	of	mitotic	exit	induced	by	this	agent.	Therefore,	the	
understanding	of	the	mechanisms	underlying	docetaxel	cytotoxicity	
will	rest	on	a	better	knowledge	of	the	link	between	checkpoint	activa-
tion	and	cell	cycle	arrest,	and	the	subsequent	induction	of	cell	death.	
The	elucidation	of	these	mechanisms	should	consider	the	signaling	
pathways,	and	possible	crosstalk	among	those	pathways,	activated	in	
a	concentration-dependent	manner.
Figure 3. Model of cell outcome according to drug concentration. A model 
for the dual mechanism of action of docetaxel is represented in the diagram. 
The main effects and outcomes are shown in a color gradient, corresponding to 
the increasing concentrations of the drug. The hypothetic correlation between 
induction of the spindle-assembly checkpoint (S-A-checkpoint) and accumula-
tion of p53 protein is shown, as well as the inverse correlation between p53, 
and the induction of p53 targets.
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